MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso ...
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling CareDx will ...
PacBio (PACB) announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics (TXG) Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes ...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics ...
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...
Insights generated from this program are intended to support future clinical diagnostic development. CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results